3Adams J A, Yin L, Brereton M L, et al. The Invitro Effect of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG rHuMGDF) on Megakaryopoiesis in Normal Subjects and Patients with Myelodysplasia and Acute Myeloid Leukaemia[J]. Br J Haematol,1997,99(1) :139-146.
二级参考文献5
1BERCHTOLD P,MCMILLAN R.Therapy of chronic idiopathic thrombocytopenic purpura in adults[J].Blood,1989,74(7):2309-2317.
2SEMPLE J W.Immune:pathophysilolgy of autoimmune thrombocytopenic purpura[J].Blood Reviews,2002,16(7):2309-2317.
3MOUSSALEM M,YASSINE N.Immune thrombocytopenic purpura in childhood:a Lebanese perspective[J].Mol Immunol,2003,39(17-18):1105-1107.
4HASHINO S,MORI A,SUZKI S,et al.Platelet recovery in patients with idiopathic thrombocytopenic purpura after eradication of Helicobacter pylo[J].Int J Hematol,2003,77(2):188-191.
5SUGIMOTO K,SASAKI M,ISOBE Y,et a1.Improvement of idiopathic thrombocytopenic purpura by antithyr therapy[J].Eur J Haematol,2005,74(1):73-74.
7Wu Z, Zhou J, Li J, et al. The feasibility of laparoscopic splenectomy for ITP patients withoutpreoperative platelet transfusion. Hepatogastroenterolog, 2012,59 ( 113 ) : 81-85.
8Sanz MA, Aledort L, Mathias SD, et al. Analysis of EQ-SD scores from two phase 3 clinical trials of romiplostim in thetreatment of immune thrombocytopenia (ITP). Value Health, 2011,14( 1 ) :90- 96.
9Cines DB,Bussel JB,Liebman HA,et al. The ITP syn- drome: Pathogenic and clinical diversity[J]. Blood,2009, 113(26) :6511-6521.
